Cas no 120685-11-2 (Midostaurin)

Midostaurin is a small-molecule kinase inhibitor that targets multiple receptor tyrosine kinases, including FLT3, KIT, and PDGFR. It is primarily used in the treatment of acute myeloid leukemia (AML) with FLT3 mutations and advanced systemic mastocytosis (SM). Midostaurin works by inhibiting aberrant signaling pathways that drive proliferation and survival of malignant cells. Its key advantages include demonstrated efficacy in combination with standard chemotherapy for FLT3-mutated AML, improving overall survival rates. The compound also exhibits activity against KIT D816V mutations, making it valuable for SM treatment. Midostaurin is administered orally, offering patient convenience, and has a well-characterized pharmacokinetic profile, supporting its clinical utility in targeted therapy regimens.
Midostaurin structure
Midostaurin structure
Product Name:Midostaurin
CAS No:120685-11-2
MF:C35H30N4O4
MW:570.637108325958
MDL:MFCD00871372
CID:178178
PubChem ID:9829523
Update Time:2025-06-29

Midostaurin Chemical and Physical Properties

Names and Identifiers

    • Benzamide,N-[(9S,10R,11R,13R)-2,3,10,11,12,13-hexahydro-10-methoxy-9-methyl-1-oxo-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3',2',1'-lm]pyrrolo[3,4-j][1,7]benzodiazonin-11-yl]-N-methyl-
    • Midostaurin
    • Midostaurin (PKC412)
    • PKC 412,[9S-(9α,10β,11β,13α)]-N-(2,3,10,11,12,13-Hexahydro-10-methoxy-9-methyl-1-oxo-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3',2',1'-lm]pyrrolo[3,4-j][1,7]benzodiazonin-11-yl)-N-methylbenzamide
    • PKC-412
    • PKC412 (Midostaurin)
    • 4'-N-benzoyl staurosprine
    • 4'-N-benzoylstaurosporine
    • Benzoylstaurosporine
    • Cgp 41 251
    • CGP 41251MIDOSTAURIN(PKC412)
    • CGP41231
    • PKC-412, CGP-41251
    • N-Benzoylstaurosporine
    • PKC 412
    • Cgp-41251
    • midostaruin
    • Midostaurin [inn]
    • N-[(2S,3S,4S,6R)-3-Methoxy-2-methyl-16-oxo-29-oxa-1,7,17-triazaoctacyclo[12.12.2.12,6.07,28.08,13.01
    • PKC412
    • Cgp 41251
    • RYDAPT
    • ID912S5VON
    • Midostaurin [USAN:INN]
    • Rydapt (TN)
    • Midostaurin(PKC412)
    • 4-N-benzoylstaurosporine
    • Staurosporine, N-Ben
    • UNII-ID912S5VON
    • N-((9S,10R,11R,13R)-2,3,10,11,12,13-Hexahydro-10-methoxy-9-methyl-1-oxo-9,13-epoxy-1H,9H-diindolo(1,2,3-gh:3',2',1'-lm)pyrrolo(3,4-j)(1,7)benzodiazonin-11-yl)-N-methylbenzamide
    • L01XE39
    • BDBM50326053
    • N-[(2S,3R,4R,6R)-3-methoxy-2-methyl-16-oxo-29-oxa-1,7,17-triazaoctacyclo[12.12.2.1^{2,6}.0^{7,28}.0^{8,13}.0^{15,19}.0^{20,27}.0^{21,26}]nonacosa-8,10,12,14(28),15(19),20(27),21,23,25-nonaen-4-yl]-N-methylbenzamide
    • Benzamide, N-(2,3,9,10,11,12-hexahydro-9-methoxy-8-methyl-1-oxo-8,12-epoxy-1H,8H-2,7b,12a-triazadibenzo(a,g)cyclonona(cde)trinden-10-yl)-N-methyl-, (8alpha,9beta,10beta,12alpha)-
    • N-benzoyl-staurosporine
    • N-((9S,10R,11R,13R)-10-methoxy-9-methyl-1-oxo-2,3,10,11,12,13-hexahydro-9,13-epoxy-1H,9H-diindolo(1,2,3-gh:3',2',1'-lm)pyrrolo(3,4-j)(1,7)benzodiazonin-11-yl)-N-methylbenzamide
    • D05029
    • Staurosporine, N-Benzoyl
    • N-[(2S,3R,4R,6R)-3-methoxy-2-methyl-16-oxo-29-oxa-1,7,17-triazaoctacyclo[12.12.2.12,6.07,28.08,13.015,19.020,27.021,26]nonacosa-8(13),9,11,14,19,21(26),22,24,27-nonaen-4-yl]-N-methyl-benzamide
    • CGP41251
    • MFCD00871372
    • [9S-(9?,10?,11?,13?)]-N-(2,3,10,11,12,13-Hexahydro-10-methoxy-9-methyl-1-oxo-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3',2',1'-lm]pyrrolo[3,4-j][1,7]benzodiazonin-11-yl)-N-methylbenzamide
    • NCGC00241102-05
    • CHEMBL608533
    • HMS3229K17
    • J-004379
    • NCGC00241102-01
    • Q6842945
    • PKC412;CGP 41251
    • 4'-N-benzoyl staurosporine
    • MIDOSTAURIN [ORANGE BOOK]
    • BRD-K13646352-001-01-2
    • NCGC00241102-02
    • Benzamide, N-((9S,10R,11R,13R)-2,3,9,10,11,12-hexahydro-10-methoxy-9-methyl-1-oxo-9,13-epoxy-1H,9H-diindolo(1,2,3-gh:3',2',1'-lm)pyrrolo(3,4-j)(1,7)benzodiazonin-11-yl)-N-methyl-
    • N-((5S,6R,7R,9R)-6-Methoxy-5-methyl-14-oxo-6,7,8,9,15,16-hexahydro-5H,14H-17-oxa-4b,9a,15-triaza-5,9-methanodibenzo[b,h]cyclonona[jkl]cyclopenta[e]-as-indacen-7-yl)-N-methylbenzamide
    • NSC800791
    • NSC 656576
    • NSC-656576
    • midostaurine
    • N-[(2S,3R,4R,6R)-3-methoxy-2-methyl-16-oxo-29-oxa-1,7,17-triazaoctacyclo[12.12.2.12,6.07,28.08,13.015,19.020,27.021,26]nonacosa-8,10,12,14,19,21,23,25,27-nonaen-4-yl]-N-methylbenzamide
    • MIDOSTAURIN [MART.]
    • HY-10230
    • CCG-101288
    • NS00073185
    • MIDOSTAURIN [USAN]
    • MIDOSTAURIN [WHO-DD]
    • GTPL5702
    • midostaurina
    • s8064
    • MIDOSTAURIN [MI]
    • midostaurinum
    • NVP-PKC412
    • 120685-11-2
    • CS-3331
    • MIDOSTAURIN [JAN]
    • NSC-800791
    • C71714
    • AKOS024457372
    • Midostaurin (JAN/USAN/INN)
    • AC-31929
    • N-[(5S,6R,7R,9R)-6-methoxy-5-methyl-14-oxo-6,7,8,9,15,16-hexahydro-5H,14H-5,9-epoxy-4b,9a,15-triazadibenzo[b,h]cyclonona[1,2,3,4-jkl]cyclopenta[e]-as-indacen-7-yl]-N-methylbenzamide
    • SCHEMBL8295379
    • CHEBI:63452
    • MIDOSTAURIN (MART.)
    • N-((5S,6R,7R,9R)-6-methoxy-5-methyl-14-oxo-6,7,8,9,15,16-hexahydro-5H,14H-5,9-epoxy-4b,9a,15-triazadibenzo(b,h)cyclonona(1,2,3,4-jkl)cyclopenta(e)-as-indacen-7-yl)-N-methylbenzamide
    • CGP 41231
    • DB06595
    • EX-A1741
    • PA-9829523
    • NCGC00484987-03
    • DA-55478
    • N-Benzoylstaurosporine , PKC412 , CGP41231 , CGP 41251
    • ARD001583
    • GLXC-02502
    • BRD-K13646352-001-03-8
    • PKC-412 (Midostaurin)
    • 1ST001583
    • SDCCGSBI-0086703.P004
    • BMGQWWVMWDBQGC-IIFHNQTCSA-N
    • MDL： MFCD00871372
    • Inchi： 1S/C35H30N4O4/c1-35-32(42-3)25(37(2)34(41)19-11-5-4-6-12-19)17-26(43-35)38-23-15-9-7-13-20(23)28-29-22(18-36-33(29)40)27-21-14-8-10-16-24(21)39(35)31(27)30(28)38/h4-16,25-26,32H,17-18H2,1-3H3,(H,36,40)/t25-,26-,32-,35+/m1/s1
    • InChI Key： BMGQWWVMWDBQGC-IIFHNQTCSA-N
    • SMILES： O1[C@@H]2C[C@H]([C@H]([C@@]1(C)N1C3C=CC=CC=3C3=C4CNC(C4=C4C5C=CC=CC=5N2C4=C13)=O)OC)N(C(C1C=CC=CC=1)=O)C

Computed Properties

  • Exact Mass: 570.22700
  • Monoisotopic Mass: 570.227
  • Isotope Atom Count: 0
  • Hydrogen Bond Donor Count: 1
  • Hydrogen Bond Acceptor Count: 4
  • Heavy Atom Count: 43
  • Rotatable Bond Count: 3
  • Complexity: 1140
  • Covalently-Bonded Unit Count: 1
  • Defined Atom Stereocenter Count: 4
  • Undefined Atom Stereocenter Count : 0
  • Defined Bond Stereocenter Count: 0
  • Undefined Bond Stereocenter Count: 0
  • XLogP3: 4.8
  • Topological Polar Surface Area: 77.7

Experimental Properties

  • Density: 1.47±0.1 g/cm3 (20 oC 760 Torr),
  • Melting Point: 235-260℃
  • Boiling Point: Not available
  • Flash Point: Not available
  • Refractive Index: 1.76
  • Solubility: Insuluble (1.5E-5 g/L) (25 oC),
  • PSA: 77.73000
  • LogP: 6.23560
  • Vapor Pressure: Not available

Midostaurin Security Information

Midostaurin Pricemore >>

Related Categories No. Product Name Cas No. Purity Specification Price update time Inquiry
SHANG HAI XIAN DING Biotechnology Co., Ltd.
B-YW619-10mg
Midostaurin
 120685-11-2 99%
10mg
 5534CNY 2021-05-07
SHANG HAI XIAN DING Biotechnology Co., Ltd.
B-YW619-50mg
Midostaurin
 120685-11-2 99%
50mg
 14715CNY 2021-05-07
SHANG HAI XIAN DING Biotechnology Co., Ltd.
B-YW619-1mg
Midostaurin
 120685-11-2 99%
1mg
 1142CNY 2021-05-07
SHANG HAI XIAN DING Biotechnology Co., Ltd.
B-YW619-5mg
Midostaurin
 120685-11-2 99%
5mg
 3427CNY 2021-05-07
MedChemExpress
HY-10230-10mM*1mLinDMSO
Midostaurin
 120685-11-2 99.95%
10mM*1mLinDMSO
 ￥2260 2023-07-26
MedChemExpress
HY-10230-1mg
Midostaurin
 120685-11-2 99.95%
1mg
 ￥770 2024-05-24
MedChemExpress
HY-10230-5mg
Midostaurin
 120685-11-2 99.95%
5mg
 ￥1800 2024-05-24
MedChemExpress
HY-10230-10mg
Midostaurin
 120685-11-2 99.95%
10mg
 ￥2880 2024-05-24
MedChemExpress
HY-10230-50mg
Midostaurin
 120685-11-2 99.95%
50mg
 ￥7238 2024-05-24
MedChemExpress
HY-10230-100mg
Midostaurin
 120685-11-2 99.95%
100mg
 ￥12000 2023-08-31

Midostaurin Suppliers

Suzhou Senfeida Chemical Co., Ltd
Gold Member
Audited Supplier Audited Supplier
(CAS:120685-11-2)Midostaurin
Order Number:sfd15603
Stock Status:in Stock
Quantity:200kg
Purity:99.9%
Pricing Information Last Updated:Friday, 19 July 2024 14:37
Price ($):discuss personally

Midostaurin Related Literature

Related Categories

Additional information on Midostaurin

Midostaurin (CAS No. 120685-11-2): A Comprehensive Overview

Midostaurin (CAS No. 120685-11-2) is a highly potent and selective inhibitor of the Fms-like tyrosine kinase 3 (FLT3), a receptor tyrosine kinase that plays a critical role in the regulation of hematopoiesis. This compound has garnered significant attention in the field of oncology due to its demonstrated efficacy in targeting FLT3-mutated acute myeloid leukemia (AML), a subtype of leukemia characterized by poor prognosis. The development of Midostaurin represents a major advancement in precision medicine, offering a tailored therapeutic approach for patients with specific genetic mutations.

The chemical structure of Midostaurin (CAS No. 120685-11-2) is designed to selectively inhibit FLT3, thereby preventing the activation of downstream signaling pathways that promote leukemia cell proliferation and survival. Recent studies have highlighted the importance of FLT3 inhibition in overcoming resistance to conventional chemotherapy and improving overall survival rates in AML patients. Clinical trials have demonstrated that Midostaurin, when administered in combination with standard chemotherapy regimens, significantly enhances remission rates and reduces the likelihood of disease relapse.

One of the most notable advancements in the research surrounding Midostaurin (CAS No. 120685-11-2) is its ability to target FLT3 internal tandem duplication (ITD) mutations, which are commonly associated with aggressive forms of AML. These mutations lead to constitutive activation of FLT3, driving uncontrolled cell growth and resistance to standard treatments. By specifically inhibiting FLT3, Midostaurin disrupts this oncogenic signaling cascade, offering a novel therapeutic strategy for patients with this challenging condition.

Recent studies have also explored the potential of Midostaurin in combination therapies, particularly with other targeted agents such as cytarabine and daunorubicin, which are cornerstone drugs in AML treatment. These combinations have shown promising results in preclinical models and early-phase clinical trials, suggesting that multi-targeted approaches may further enhance the efficacy of Midostaurin (CAS No. 120685-11-2) in treating AML.

The pharmacokinetics and safety profile of Midostaurin have been extensively studied, with data indicating that it is well-tolerated by most patients when administered at recommended doses. Common side effects include nausea, diarrhea, and fatigue, which are generally manageable with supportive care. Ongoing research is focused on optimizing dosing regimens and identifying biomarkers that predict response to therapy, further refining its use in clinical practice.

In addition to its role in AML treatment, emerging evidence suggests that Midostaurin may have applications in other hematologic malignancies characterized by FLT3 activation or other related signaling abnormalities. For instance, preclinical studies have explored its potential utility in chronic myelomonocytic leukemia (CMML) and other myeloid neoplasms, where FLT3 mutations are also prevalent.

The development of Midostaurin (CAS No. 120685-11-2) underscores the importance of targeted therapies in modern oncology, emphasizing the need for personalized treatment approaches based on molecular profiling. As research continues to uncover new insights into FLT3 biology and resistance mechanisms, it is anticipated that Midostaurin will remain at the forefront of innovative cancer therapies.

In conclusion, Midostaurin represents a significant milestone in the treatment of FLT3-mutated AML, offering a precise and effective therapeutic option for patients who previously had limited treatment choices. With ongoing advancements in research and clinical application, this compound holds immense promise for improving outcomes in hematologic malignancies and beyond.

120685-11-2 (Midostaurin) Related Products

Recommended suppliers
Suzhou Senfeida Chemical Co., Ltd
(CAS:120685-11-2)Midostaurin
sfd15603
Purity:99.9%
Quantity:200kg
Price ($):Inquiry
Email